Compare British American Tobacco PLC (BTI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs ResMed Inc. — how do they compare? British American Tobacco PLC trades at $56.02 (market cap $122.36B), while ResMed Inc. trades at $225.38 (market cap $32.61B). The key difference: British American Tobacco PLC is far larger — about 3.8× ResMed Inc.'s market cap, and British American Tobacco PLC pays the higher dividend (5.88%). Which is the better fit depends on your goals.
| BTI | RMD | |
|---|---|---|
Market Cap | $122.36B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $293.73 |
52-Week Low | $50.39 | $182.82 |
Enterprise Value | $166.31B | $31.97B |
Dividend Yield | 5.88% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $55.93, down 1.96% today, with a bearish technical signal and mixed earnings history. The company maintains strong profitability with an 83.56% gross margin and 24.99% net income margin, supported by a P/E of 14.48. Recent news highlights strategic tech partnerships and workforce restructuring to drive efficiency.
The outlook is cautious due to declining cash flow and regulatory risks, but the 5%+ dividend yield and analyst buy consensus (66.7%) offer value. Upside depends on successful transition to next-generation products, while core combustible declines and debt levels pose challenges.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
